Francesco Bertolini, MD, PhD

Education and PHD/Masters/Courses

1986 MD, University of Milan
1989 Board in Clinical and Laboratory Hematology
1993 PhD in Experimental Medicine, university of Amsterdam

Titles (included other positions covered)

1988-1990	Visiting scientist at the Thomas Jefferson University in Philadelphia, USA
1990-1995	Medical Assistant at the Department of Hematology in the Policlinico Hospital in Milan.
1995-1998	Vice-Director at the Division of Oncology of the Maugeri Foundation, Italy.

Clinical and research carried out at IEO

Dr. Bertolini works in the Laboratory of Hematology/Oncology at the European Institute of Oncology in Milan, where he takes care of patients and leads research programs in hematology/oncology, angiogenesis and stem cell biology.

Dr Bertolini has been involved in different cancer-related fields, namely blood transfusion, stem cell transplantation, animal models of cancer and anti-angiogenic therapy over a period of thirty years, generating robust networks with the international experts in the field. These achievements were obtained combining the running of a translational research laboratory with clinical activities, caring for cancer patients affected by haematological malignancies.

In the 1985-1995 decade Dr Bertolini has developed and published a novel procedure for the preparation and storage of platelet concentrates that is currently in use in most transfusion centres worldwide. In the same timeframe he was also instrumental in the development of blood filters able to reduce alloimmunization and transfusion reactions.

From 1990 to 1998 he pioneered the field of cord blood collection and transplant. He realized in Milan the first EU cord blood bank and the first Italian cord blood transplants in patients. He also published procedures for ex vivo stem cell expansion and the first EU pilot clinical trial in the field.

From 1998 onward Dr Bertolini was involved in the development of anti-angiogenic therapies of cancer, including haematological malignancies. His research has led to novel biomarkers and to clinical protocols involving anti-angiogenic drugs.

Since 2012 he is investigating the role of the white adipose tissue and its progenitors in the progression and metastatic spread of neoplastic cells.

Publications

As of January 1st, 2014: >165 peer reviewed papers, >7500 citations, h-index 46 (Web of Science).
Two papers (FB first or last author) have >300 citations, 6 papers (5 out of 6 with FB first or senior author) have >200 citations, 17 (11 out of 17 with FB first or senior author) have >100 citations.

Congresses

Invited Speaker and/or chairman in international meetings of the American Association of Hematology, the American Association for Cancer Research and many others.